In the first half of 2022, Jafron gained an operating revenue of 1554 million yuan (about $215.2 million), representing a 30.8% expansion year on year. In the third quarter, Jafron got a series of good news:

1. Being one of the top 50 leading companies on the 2021 ChiNext by market cap

2. Ranking 11^th in China’s Top 20 Medical Device (including IVD) Enterprise List

3. Being included in the annual quality credit list of Class A medical device manufacturers in Guangdong Province for 11 years straight

Those honors come from Jafron’s commitment to pursuing high-quality development by concentrating on quality, trustworthiness, and R&D.

Copyright photo from https://www.jafron.com/content-18-1290-1.html

With a concentration on innovation, Jafron keeps consolidating the foundation for R&D development. We heavily invested in two new bases, which are expected to gain Jafron stronger momentum in pharmaceutical development and production. Meanwhile, Jafron has obtained three Certificates of China Export Commodity Brand this year. The new blood purification devices are applied in a wider scope, in terms of their targeted symptoms and implementation in other countries, with over 80 countries approving the application of Jafron medical devices. Besides, a growing number of solid evidence are gradually disseminating the dispute over their efficacy.

The company has boosted its contribution to Hepatology and severe acute disease research while maintaining its stable development in Nephrology, driving more brand-new devices, like the KHA Series and CA series to the market, all of which mirror Jafron’s huge development potential. 

Jafron also places its emphasis on charity. Over 15 million yuan was donated this summer for poverty alleviation and rural revitalization. The Jafron· HerHealth activity was initiated. Over 800 thousand yuan was provided, helping 1441 needy females to purchase health insurance targeting the 7 common cancers. The effect of the insurance can last for 3 years, which will prevent the females from falling or slicking back into poverty due to illness, tackling the severe issue at its source. 

Copyright photo from https://www.jafron.com/content-18-1291-1.html

In the past three months, Jafron has kept investing in pharmaceutical R&D, aiming to provide more creative and efficacious devices for patients around the globe. Going forward, the company will shoulder its social responsibilities, generating more positive outcomes. Now, time to move to the next stage.